BR112021008614A2 - Medicamentos que contêm riboflavina que exibem fluidez aprimorada - Google Patents

Medicamentos que contêm riboflavina que exibem fluidez aprimorada

Info

Publication number
BR112021008614A2
BR112021008614A2 BR112021008614A BR112021008614A BR112021008614A2 BR 112021008614 A2 BR112021008614 A2 BR 112021008614A2 BR 112021008614 A BR112021008614 A BR 112021008614A BR 112021008614 A BR112021008614 A BR 112021008614A BR 112021008614 A2 BR112021008614 A2 BR 112021008614A2
Authority
BR
Brazil
Prior art keywords
exhibit improved
improved fluidity
containing riboflavin
riboflavin
medications containing
Prior art date
Application number
BR112021008614A
Other languages
English (en)
Inventor
Markus Nowotny
Zdravka Misic
Original Assignee
Dsm Ip Assets Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dsm Ip Assets Bv filed Critical Dsm Ip Assets Bv
Publication of BR112021008614A2 publication Critical patent/BR112021008614A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

medicamentos que contêm riboflavina que exibem fluidez aprimorada. a formulação dos agentes anti-hipertensivos que são cristalinos tendo um formato de placa geral pode ser difícil visto que frequentemente não exibem propriedades de fluidez satisfatórias. a adição de riboflavina seca por aspersão aprimora surpreendentemente a fluidez desses agentes.
BR112021008614A 2018-11-07 2019-10-09 Medicamentos que contêm riboflavina que exibem fluidez aprimorada BR112021008614A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18204934 2018-11-07
EP18204935 2018-11-07
PCT/EP2019/077270 WO2020094319A1 (en) 2018-11-07 2019-10-09 Medicaments containing riboflavin exhibiting improved flowability

Publications (1)

Publication Number Publication Date
BR112021008614A2 true BR112021008614A2 (pt) 2021-11-03

Family

ID=68136423

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021008614A BR112021008614A2 (pt) 2018-11-07 2019-10-09 Medicamentos que contêm riboflavina que exibem fluidez aprimorada

Country Status (9)

Country Link
US (1) US11975007B2 (pt)
EP (1) EP3876912B1 (pt)
JP (1) JP7443663B2 (pt)
KR (1) KR20210089219A (pt)
CN (1) CN112955128A (pt)
BR (1) BR112021008614A2 (pt)
ES (1) ES2949057T3 (pt)
PL (1) PL3876912T3 (pt)
WO (1) WO2020094319A1 (pt)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1904699A (en) 1929-05-24 1933-04-18 James A Singmaster Production of cement
EP0272336B1 (de) 1986-12-18 1991-10-23 Kurt H. Prof. Dr. Bauer Gegenüber Lichteinfluss stabilisiertes Nifedipin-Konzentrat und Verfahren zu seiner Herstellung
US5034389A (en) 1989-07-28 1991-07-23 Coors Biotech, Inc. Riboflavin composition and method for production
DE4014262A1 (de) 1990-05-04 1991-11-07 Basf Ag Gut rieselfaehige, nichtstaubende bindemittelfreie riboflavinspruehgranulate oder -mikrogranulate aus reinem riboflavin und ein verfahren zu deren herstellung
DE19515971A1 (de) 1995-05-02 1996-11-07 Bayer Ag Kombinationspräparate mit vaskulärer Wirkung
US6093715A (en) 1999-03-24 2000-07-25 Basf Aktiengesellschaft Process for producing riboflavin-containing granules
US6723346B1 (en) 1999-04-30 2004-04-20 Roche Vitamins Inc. Process for preparing spray granules containing riboflavin
JP4964587B2 (ja) 2004-05-11 2012-07-04 第一三共株式会社 Ｂｈ４反応性高フェニルアラニン血症治療剤
CN104434823A (zh) 2013-09-17 2015-03-25 许昌恒生制药有限公司 一种盐酸马尼地平片剂及其制备方法

Also Published As

Publication number Publication date
JP2022505126A (ja) 2022-01-14
EP3876912A1 (en) 2021-09-15
US20210401847A1 (en) 2021-12-30
US11975007B2 (en) 2024-05-07
EP3876912B1 (en) 2023-04-19
WO2020094319A1 (en) 2020-05-14
PL3876912T3 (pl) 2023-08-07
CN112955128A (zh) 2021-06-11
KR20210089219A (ko) 2021-07-15
ES2949057T3 (es) 2023-09-25
JP7443663B2 (ja) 2024-03-06

Similar Documents

Publication Publication Date Title
BR112018004175A2 (pt) novo composto pirazolo[3,4-d]pirimidina ou sal deste
BR112018012756A2 (pt) compostos heterocíclicos como imunomoduladores
MX2018001729A (es) Compuestos antivirales de fosfodiamida de ester de beta-aminoacido.
CU20190058A7 (es) Composiciones de aminoácidos relacionadas con mejoras de la función hepática
NZ733135A (en) Fused pyrimidine compounds for the treatment of hiv
BR112017007460A2 (pt) inibidores de di-hidropirrolopiridina de ror-gama
MY196909A (en) Boronic acid derivatives and therapeutic uses thereof
MD3313817T2 (ro) Derivați biciclici, un procedeu pentru prepararea lor și compozițiile farmaceutice care îi conțin
BR112015022643A2 (pt) inibidores diidro-pirrolpiridinona
PH12016500170A1 (en) Formulation of syk inhibitors
BR112015018087A8 (pt) composto, composição farmacêutica e uso
EA201590674A1 (ru) Производные 5-фенокси-3h-пиримидин-4-она и их применение в качестве ингибиторов обратной транскрипазы вич
BR112017001456A2 (pt) sistemas de prótese provisória e métodos de utilização dos mesmos
BR112019015904A2 (pt) Sistemas e métodos para a fabricação de comprimidos, incluindo comprimidos farmacêuticos
BR112017009021A2 (pt) formulação farmacêutica de anticorpo anti-tnfa
CU20180027A7 (es) DERIVADOS DE PIRROLO[2,3-d]PIRIMIDINA, ÚTILES COMO INHIBIDORES DOBLES DE DYRK 11CLK1 Y COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN
WO2015120237A3 (en) 4'-difluoromethyl substituted nucleoside derivatives as inhibitors of influenza rna replication
MX2018009459A (es) Derivado de sulfonamida y composicion farmaceutica que contiene el mismo.
BR112017000246A2 (pt) composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, e, uso de um composto ou de um sal
BR112018074985A2 (pt) composições antibacterianas
WO2017147557A8 (en) Novel prna three-way junctions
MX2018015872A (es) Derivados de benzodioxano y su uso farmaceutico.
BR112017026904A2 (pt) formulações farmacêuticas injetáveis de lefamulina
MX2021012029A (es) Composicion farmaceutica de corticosteroide soluble.
MA46266B1 (fr) Formes cristallines

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]